OneSkin develops premium skincare products powered by OS-01, a peptide that targets cellular senescence to slow skin aging. OS-01 works by preventing buildup of senescent cells, supporting tissue repair, and boosting collagen and hyaluronic acid markers, with lab tests showing thicker epidermis and reduced biological age in skin models. The company differentiates itself by grounding its products in senotherapy science, validating effects in lab models, and combining a direct-to-consumer, subscription-driven model with Amazon and professional channels. Its goal is to expand internationally, develop new products, and advance clinical studies to further validate OS-01 and extend skin health.
Company Size
51-200
Company Stage
Series A
Total Funding
$40M
Headquarters
San Francisco, California
Founded
2016
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?